Technavio's report indicates that the global market for Pulmonary Arterial hypertension (PAH) drugs Market will increase by USD 2.26 billion, growing at a CAGR of 6.78% through 2028. The growing number of PAH cases, largely driven by aging and lifestyle-related cardiovascular issues, is pushing the demand for effective therapies. Oral medications, particularly endothelin receptor antagonists (ERAs), are becoming a popular choice for their patient-friendly administration. North America is set to lead in market growth, contributing around 47% of the overall share, supported by its strong healthcare infrastructure and high level of disease awareness.

Click here to download Pulmonary Arterial Hypertension (Pah) Drugs Market Sample PDF Click here to Contact us for more Information